RxDoctor Payments Data

David Grasic, MD

Retina Specialist · Edmond, OKNPI 1982256558

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Kyowa Kirin, Inc. at 32.5% of the total. Reporting peaked in 2024 at $2,319 and has fallen 67.5% since, to $753 in 2025.

$5,957in general payments, 2019–2025

Across 80 payments — averaging $74.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kyowa Kirin, Inc.$2K
  • AbbVie$1K
  • Alimera Sciences, Inc.$503
  • Regeneron Healthcare Solutions, Inc.$465
  • Genentech USA, Inc.$287
  • Astellas Pharma US Inc$280
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$1,05018%
  • Speaking & faculty fees$3506%
  • Travel & lodging$1,46925%
  • Food & beverage$3,08852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,429,568
Medicare patients
857
Services billed
8,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$21,658
Difluprednate47$4,719
Brimonidine Tartrate50$4,271
Prednisolone Acetate107$4,174
Alphagan PBrimonidine Tartrate14$4,039
Latanoprost106$2,324
Ketorolac Tromethamine54$1,472
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat61$904
ValacyclovirValacyclovir Hcl14$514
ErythromycinErythromycin Base30$353
Timolol Maleate24$250
Prednisone44$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P$1,391$25,69732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other retina specialist in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →